Analysts Say Buy the Dip on This New Drug Stock

CNST stock went public just a few weeks back

Aug 13, 2018 at 9:42 AM
facebook twitter linkedin

The shares of Constellation Pharmaceuticals Inc (NASDAQ:CNST) are up 5% to trade at $10.35, after BMO started coverage on the cancer specialist with an "outperform" recommendation and a $19 price target -- a nearly 93% premium to last Friday's close. The analyst in coverage said the stock still has not priced in the full valuation of its myelofibrosis treatment, CPI-0610, and could potentially hit $35 per share once this is realized.

J.P. Morgan Securities and Oppenheimer both took a glass-half-full approach to CNST stock, both initiating coverage with an "outperform" rating and $17 and $21 price targets, respectively. The former brokerage firm said CNST stock's massive drop from its mid-June initial public offering (IPO) has created an "interesting/compelling entry point ahead of more robust proof-of-concept data."

Specifically, Constellation Pharmaceuticals stock went priced its IPO at $15 per share back on July 18, before opening the next day at $11.48. The shares have continued to trend lower since then, bottoming at a record low of $9 one week ago today.

cnst stock daily chart aug 13


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!



Special Offers from Schaeffer's Trading Partners